Acute @entity583 in @entity6 and significance of XXXX as a prognostic factor.

@entity1 @entity8 @entity712 @entity101 @entity6 @entity28 @entity908 @entity583 @entity1455 @entity204
@entity6 has been associated with high mortality rates in @entity1 with @entity583 ( @entity583 ). To better define prognosis in this population, the clinical course of 183 diabetics with @entity583 was studied. In-hospital mortality for all @entity1 was 28% (52 of 183 @entity1 ). Mortality was significantly higher in @entity1 with prior @entity583 than in @entity1 without prior @entity583 (41 vs 18%, p less than 0.01) and was significantly higher in @entity1 than in @entity1 (37 vs 19%, p less than 0.01). The 2-fold increase in mortality among @entity6 @entity1 was observed both in @entity1 with and without prior @entity583 . The excess mortality among @entity6 @entity1 was attributable to their increased risk for severe @entity712 ( @entity712 ) and @entity1455 . @entity204 due to @entity712 occurred in 22% of all @entity6 @entity1 with @entity583 compared with 6% of the @entity6 @entity1 (p less than 0.01). @entity204 resulting from complications other than @entity712 was similar for both sexes. There were no male-female differences in the history of prior @entity583 , systemic @entity101 , @entity28 , @entity8 , frequency of Q-wave @entity583 , anterior @entity583 or peak @entity908 kinase levels to account for the high risk for @entity712 in @entity6 @entity1 . It is therefore concluded that @entity6 @entity1 with @entity583 are at increased risk for @entity204 due to @entity712 , and that this risk is not readily attributable to known conditions associated with @entity712 .
